Landos Biopharma, Inc. LABP NASDAQ

Landos Biopharma, Inc. (LABP) reported revenue of $0 in its most recent fiscal year. The company reported a net loss of $22M in its most recent fiscal year, with earnings trending at 5.4%/yr. The company has not reported a profit in any of the last 4 years tracked. The gross margin is 98.9% (high), reflecting the company's pricing power. With a market cap data available and MOAT composite score of 46/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (40/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 6-year history, the company was profitable in 0 of 6 years — a mixed long-term record
• INCOME (?/100, Fail) — the company is currently operating at a loss
• MOAT (46/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 41/100 with 1/5 criteria passed.